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Abstract
Background: Several transgenic animal models genetically predisposed to develop Alzheimer's
disease (AD)-like pathology have been engineered to facilitate the study of disease pathophysiology
and the vetting of potential disease-modifying therapeutics. The triple transgenic mouse model of
AD (3xTg-AD) harbors three AD-related genetic loci: human PS1M146V, human APPswe, and human
tauP301L. These mice develop both amyloid plaques and neurofibrillary tangle-like pathology in a
progressive and age-dependent manner, while these pathological hallmarks are predominantly
restricted to the hippocampus, amygdala, and the cerebral cortex the main foci of AD
neuropathology in humans. This model represents, at present, one of the most advanced preclinical
tools available and is being employed ever increasingly in the study of mechanisms underlying AD,
yet a detailed regional and temporal assessment of the subtleties of disease-related pathologies has
not been reported.
Methods and results: In this study, we immunohistochemically documented the evolution of AD-
related transgene expression, amyloid deposition, tau phosphorylation, astrogliosis, and microglial
activation throughout the hippocampus, entorhinal cortex, primary motor cortex, and amygdala
over a 26-month period in male 3xTg-AD mice. Intracellular amyloid-beta accumulation is
detectable the earliest of AD-related pathologies, followed temporally by phospho-tau,
extracellular amyloid-beta, and finally paired helical filament pathology. Pathology appears to be
most severe in medial and caudal hippocampus. While astrocytic staining remains relatively
constant at all ages and regions assessed, microglial activation appears to progressively increase
temporally, especially within the hippocampal formation.
Conclusion: These data fulfill an unmet need in the ever-widening community of investigators
studying 3xTg-AD mice and provide a foundation upon which to design future experiments that
seek to examine stage-specific disease mechanisms and/or novel therapeutic interventions for AD.
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Background
Alzheimer's disease (AD) represents the most common
age-related neurodegenerative disorder and cause of
dementia worldwide. The prevalence of AD is predicted to
increase significantly to affect over 100 million people
worldwide by the year 2050 [1]. With this dire prediction,
it has become imperative to dissect the pathophysiologic
mechanisms intrinsic to AD in an effort to eventually
devise disease course-modifying therapies. Individuals
afflicted with AD harbor two pathological signatures
within their brains: extracellular amyloid plaques and
neurofibrillary tangles (NFTs), which are identifiable only
upon post-mortem examination. Extracellular plaques are
comprised of proteinaceous aggregates of amyloid beta
(Aβ) peptides, ubiquitin, various proteoglycans, pro-
teases, serum-related molecules, as well as numerous
other proteins [2]. The major amyloidogenic components
of plaque, Aβ 1–40 and 1–42 peptides, are the proteolyti-
cally liberated products that arise from the enzymatic
processing of amyloid precursor protein (APP), a type 1
transmembrane protein. NFTs are the result of intraneuro-
nal hyperphosphorylated paired helical filaments of the
microtubule-associated protein tau. The seminal work by
Drs. Heiko and Eva Braak demonstrated that these pathol-
ogies proceed in a definable temporal and spatial pattern
within the human brain [3]. Stage A of amyloid accumu-
lation represents the presence of amyloid patches in the
basal neocortex and in poorly myelinated temporal areas
such as perirhinal and entorhinal areas; the spreading of
amyloid deposition to neocortical areas and the hippoc-
ampus is indicative of Stage B, while Stage C includes
appearance of amyloid deposits in highly myelinated
areas of the cortex and neocortex. The evolution of NFTs
in the AD brain proceeds through six distinct stages that to
some extent overlap with those of amyloid deposition.
Stage I is defined by NFT appearance in cell projections
comprising the trans-entorhinal region of the temporal
lobe, whereas evidence of NFT pathology in the entorhi-
nal region, hippocampus/temporal pro-neocortex is
indicative of Stages II and III, respectively. Stages IV-VI of
NFT formation includes progression to the neocortex and
areas adjoining the neocortex.
To elucidate the varying pathophysiologic mechanisms
underlying AD progression and to assess potential dis-
ease-modifying therapeutics in a preclinical in vivo setting,
investigators have turned to transgenic mouse models
harboring mutated human genes associated with the
familial forms of AD. Although no single transgenic
model recapitulates the human disease in all aspects of
neuropathology and behavior, some assumptions can be
made as to which model best fits specific criteria of AD.
Amyloid-based transgenic mouse models exist that over-
express wild-type or mutant forms of APP (i.e., Tg2576;
[4]), leading to extracellur Aβ peptide accumulation into
plaque-like deposits, synaptic loss, microgliosis, astrocy-
tosis, and cerebrovascular angiopathy [5-8,4,9,10]. Most
of these models exhibit differential behavioral pheno-
types related to significant learning and memory impair-
ment, spatial deficits, and at times, increased aggression.
At least nine transgenic mouse models have been created
to study consequences of pathogenic tau expression [11-
16]. All models show pathology of varying severity,
including models overexpressing normal human tau.
The triple-transgenic Alzheimer's disease (3xTg-AD)
mouse, created in the laboratory of Dr. Frank LaFerla, rep-
resents one of the most state-of-the-art and biologically
relevant mouse model for AD described to date. The 3xTg-
AD mouse model was generated by co-microinjection of
the human APPswe and tauP301L genes, both under the tran-
scriptional control of a modified Thy1.2 promoter, into
single-cell homozygous mutant PS1M146V knock-in mouse
embryos [17]. These mice develop intracellular Aβ, amy-
loid plaques and NFTs in a progressive and age-related
pattern, where the pathologies are predominantly
restricted to the hippocampus, amygdala, and the cerebral
cortex [18]. These mice also exhibit deficits in synaptic
functioning, including long-term potentiation (LTP) [17],
and learning/memory behaviors that are similarly mani-
fested in an age-dependent manner [19]. These early
papers describing the derivation and initial characteriza-
tion of pathological progression in 3xTg-AD mice was
limited in terms of temporal and regional evolution of
particular AD-related hallmarks. Moreover, it has been
difficult to glean from those reports as to whether one
gender was exclusively studied or whether experimental
groups consisting of mixed genders were employed [17].
A detailed regional and temporal assessment of the subtle-
ties of disease-related brain pathologies that arise in 3xTg-
AD mice over much of their lifespan has yet to be
reported. Absence of such information may lead one to
improperly initiate long-term experiments designed to
address specific hallmarks of AD-related pathology. To
that end, we have systematically examined the temporal
and spatial progression of human APPswe  transgene
expression, appearance of intracellular and extracellular
Aβ1–42, human tauP301L transgene expression, appearance
of pathogenic phospho-tau, and evidence of microglial
activation and astrogliosis in male 3xTg-AD mice from 2
to 26 months of age.
Results
Human APPswe Transgene Expression
In the present study, we sought to immunohistochemi-
cally document the temporal and regional evolution of
AD-related transgene expression, amyloid deposition, tau
phosphorylation, astrogliosis, and microglial activation
throughout the hippocampus, amygdala, primary motorBMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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cortex, and entorhinal cortex over a 26-month period in
male 3xTg-AD mice (Antibodies employed in this study
are shown in Table 1 and Nissl-stained brain regions of
interest depicted in Figure 1). To sufficiently garner
detailed insight into how AD-related pathologies arise in
3xTg-AD mice, animals were sacrificed at 2, 3, 6, 9, 12, 15,
18, and 26 months of age for subsequent immunohisto-
chemical processing (N = 4 per time point). Amyloid
pathology that develops in these mice derives from the
proteolytic processing of the human APP transgene prod-
uct that harbors the Swedish double mutation (K595N/
M596L; [20]) and M146V knock-in mutation in preseni-
lin 1 [21,22] that, in combination, lead to the marked
overproduction and progressive accumulation of the
fibrillogenic peptide, Aβ1–42 [23]. The hAPPswe transgene,
as well as the tauP301L transgene, is under the transcrip-
tional control of Thy1.2 gene promoter, which results in
transgene expression specifically within neuronal popula-
tions beginning early in post-natal development and con-
tinuing into adulthood [24]. Human APPswe transgene
expression, as assessed using the APP Y188 antibody
(AbCam), which recognizes the NPXY amino acid motif
of the hAPP protein localized amino terminal to the cleav-
age fragment of Aβ, was detectable in 3xTg-AD mouse
brain beginning at the 2-month time point throughout
the pyramidal neurons of the hippocampus (rostral, inter-
mediate, and caudal; Figure 2), layer II and III neurons of
the entorhinal cortex (Figure 3A–H), and primary motor
cortex (Figure 4A–H). Staining intensities for hAPPswe
transgene product qualitatively appear to stabilize from 6
months and older in all of the regions of the hippocam-
pus and entorhinal cortex examined (Figures 2 and 3A–
H). Interestingly, in the amygdala, hAPPswe expression is
not detected by the Y188 antibody consistently until 6
months of age (Figure 5A–H).
Patterns of Intracellular and Extracellular Aβ Peptide 
Accumulation
Assessment of Aβ peptide deposition was performed using
two antibodies with differing specificity: 6E10, which rec-
ognizes amino acid residue 1–16 of beta-amyloid, but
also reacts with that identical epitope within non-proteo-
lytically processed hAPP; and monoclonal antibody 12F4,
which is specifically reactive to the C-terminus of Aβ1–42.
The expression of APP/Aβ as detected by 6E10 reveals sim-
ilar cell-associated patterns of staining to those observed
Representative Nissl-stained brain sections from 3xTg-AD mice depicting regions examined by immunohistochemistry in this  study Figure 1
Representative Nissl-stained brain sections from 3xTg-AD mice depicting regions examined by immunohisto-
chemistry in this study. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 6 months 
of age and were processed for Nissl staining. Primary motor cortex (PMC) at Bregma 0.5 mm (A), amygdala (Amy) at Bregma 
-0.8 mm (B), CA1 hippocampal sections at Bregma -1.8 mm (C), at Bregma -2.5 mm (D), and at Bregma -2.8 mm (E), as well as 
entorhinal cortex (Ent) at Bregma -2.8 mm (E) are outlined by dotted boxes to illustrate the sub-regions of the brains exam-
ined in this study. Photomicrographs were obtained at 1.25×.
A B
C D E
PMC
Amy
CA1 CA1
CA1/Sub
Ent
Bregma 0.5 mm Bregma -0.8 mm
Bregma -1.8 mm Bregma -2.5 mm Bregma -2.8 mmBMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Human amyloid precursor protein transgene expression is readily detectable within the pyramidal cell layer of 3xTg-AD mouse  hippocampus from 2 to 26 months of age Figure 2
Human amyloid precursor protein transgene expression is readily detectable within the pyramidal cell layer of 
3xTg-AD mouse hippocampus from 2 to 26 months of age. Coronal mouse brain sections (30 μm) were prepared 
from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), 
and 26 months of age (H, P, X) and were processed for immunohistochemistry to detect human amyloid precursor protein 
(hAPP) A4 using the Y188 monoclonal antibody. CA1 hippocampal sections at Bregma -1.8 mm (A–H), at Bregma -2.5 mm (I-
P), and at Bregma -2.8 mm (Q-X), were examined for regional and temporal patterns of hAPPswe transgene expression and 
photomicrographs were obtained at 10×. The inset in panel X represents a 40× digitally magnified image of the photomicro-
graph for better visualization of stained cell morphology. Scale bar in D represents 200 μm.
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Figure 3 (caption on next page)
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in sections stained with the hAPP-specific antibody
(Y188) through 12 months of age (Figures 3I–P, 4I–P, 5I–
P, and 6). The co-staining of APP/Aβ begins to appear in
CA1 neurons at approximately 3 months of age in the cau-
dal most region of the hippocampus (Figure 6R), neurons
in layer II and III of the entorhinal cortex (Figure 3J), and
neurons of the primary motor cortex (Figure 4J). Evidence
of 6E10 staining in the amygdala does not become appre-
ciable until 6 months of age (Figure 5K). The intracellular
expression of APP/Aβ is confined to the pyramidal layer of
the hippocampus and all other brain regions until devel-
opment of extracellular deposition begins to be apparent
at ages greater than 15 months (Figures 3O, 4O, 5O, and
6V, G, O). With all cell-associated immunopositive signal,
APP/Aβ staining is limited to the cell bodies, with little to
no staining of fibers residing in the radiatum of the hip-
pocampus. Plaques that appear at 18 and 26 months of
age are found in the stratum oriens, stratum lucidium and
radiatum of the hippocampus, and layers V and VI of the
entorhinal cortex, with a majority of the extracellular
plaques developing within the subiculum.
To confirm that the extracellular plaque-like deposition
pattern was the result of accumulated Aβ1–42 peptide, adja-
cent sections were stained with the anti-Aβ1–42 antibody
12F4 (Figures 3Q–X, 4Q–X, 5Q–X, and 7). Using a pep-
tide competition experiment, this antibody was shown to
specifically recognize extracellular Aβ1–42 (Figure 7A-D). It
is readily apparent that Aβ1–42-reactive deposits accumu-
late in the hippocampus starting at the subiculum/CA1
interchange at 15 months of age (Figure 7Z). Prior to this
age, Aβ1–42 accumulation in the hippocampus is below the
threshold of detection for this antibody in male 3xTg-AD
mice. Interestingly the more rostral areas of the hippoc-
ampus even at the 15-month time point do not show any
Aβ1–42 reactivity (Figure 7J, R). By 18 months of age, the
Aβ1–42  burden is rather significant with large dense
plaques apparent in the caudal hippocampus at the area
of the subiculum/CA1 interchange (Figure 7AA) with
smaller deposits appearing in the stratum oriens and
radiatum flanking the pyramidal layer of the hippocam-
pus (Figure 7K, S). By 26 months the dense cored extracel-
lular Aβ1–42  deposits have spread throughout the
hippocampus. Intriguingly, Aβ1–42 reactivity is lacking in
the cells that comprise the pyramidal layer of the CA1,
which robustly stained with 6E10 at the same age (Figure
6H, P, X). Patterns of Aβ1–42 deposition in the entorhinal
cortex begins in the deeper layers at 18 months of age (Fig-
ure 3W) and spreads to the more superficial layers,
encompassing the entire entorhinal cortex by 26 months
(Figure 3X). Similar observations of extracellular Aβ 1–42
deposition can be seen at 18 and 26 months in amygdala
and primary motor cortex (Figures 4W, X, and 5W, X).
An early role of intracellular Aβ in neuronal dysfunction
has been proposed (reviewed by [25]). Oddo et al. previ-
ously reported 3xTg-AD mice first show evidence of
intraneuronal Aβ1–42 accumulation at ages when cognitive
deficits begin to surface [19], and that as these mice age,
they exhibit decreases in intraneuronal Aβ immunoreac-
tivity with a concomitant increase in extracellular plaque
load [26]. Historically, it has been technically difficult to
detect intracellular Aβ with high confidence of specificity.
To further detail the evolution of intracellular Aβ pathol-
ogy in 3xTg-AD mice, we employed an immunohisto-
chemical staining method optimized for visualization of
intracellular Aβ1–42 peptide [27,28], which more readily
unmasks intracellular Aβ peptide epitopes than standard
formic acid epitope retrieval methods used for extracellu-
lar plaque immunohistochemistry. Using this methodol-
ogy the employs a different anti-Aβ 42 antibody
(Biosource/Invitrogen Aβ1–42), we have been able to
reproducibly detect intracellular Aβ1–42 and demonstrated
antibody specificity with cognate peptide competition
tests (Figure 8A–D). The Covance/Signet 12F4 anti-Aβ1–42
antibody was not used with microwave pretreatment to
detect intraneuronal Aβ. With formic acid pretreatment,
the 12F4 antibody only labeled extracellular plaques and
not Aβ localized intraneuronally. Evidence of intracellular
Aβ1–42 immunopositivity using the Biosource/Invitrogen
Aβ1–42  antibody was found in 3xTg-AD mouse brains
beginning as early as 2 months of age (Figure 8E, M, U),
and stably present throughout the time points assessed.
The majority of intracellular Aβ1–42 expressing cells were
detected outside of the pyramidal layer of the hippocam-
pus, and found within the stratum oriens of the hippoc-
Entorhinal cortex-resident human APPswe transgene expression and Aβ peptide deposition evolve on similar timescales as  observed in the 3xTg-AD hippocampus Figure 3 (see previous page)
Entorhinal cortex-resident human APPswe transgene expression and Aβ peptide deposition evolve on similar 
timescales as observed in the 3xTg-AD hippocampus. Coronal mouse brain sections (30 μm) were prepared from 
3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), and 
26 months of age (H, P, X) and were processed for immunohistochemistry to detect the human Swedish mutant amyloid pre-
cursor protein (hAPPswe) transgene product using the Y188 monoclonal antibody (A–H), human amyloid precursor protein 
(hAPP) and Aβ peptides using the 6E10 monoclonal antibody (I-P), and extracellular Aβ1–42 deposition using the 12F4 mono-
clonal antibody (Q-X). Entorhinal cortex was examined for patterns of immunopositivity and photomicrographs were 
obtained at 10×. The insets in panels H, P, and X represent 40× digitally magnified images of designated photomicrographs for 
better visualization of immunopositive cell/pathology. Scale bar in D represents 200 μm.BMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Figure 4 (caption on next page)
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ampus (Figure 8E–T), the subiculum (Figure 8U-AB), and
the corpus callosum (Figure 8M–T).
Progression of Tau Pathology
Tau, which is expressed as 6 soluble isoforms from a
genetic locus found on chromosome 17, is a microtubule-
associated protein with numerous functions within the
neuron [29-31]. One such cellular role is its ability to sta-
bilize and promote the polymerization of microtubules
[32-35]. This function has led to the hypothesis that the
inability of tau to adequately bind and promote polymer-
ization of microtubules would result in diminished trans-
port within a neuron. Since it has been shown that the
abnormal morphologic entity in AD brains known as the
neurofibrillary tangle is comprised primarily of tau [36], it
has been proposed that abnormalities of tau, directly or
indirectly, play a central role in the pathogenesis of AD by
progressively leading to a loss of fast axonal transport. A
number of abnormalities of tau have been identified or
suggested in AD neurons. These abnormalities include
formation of tau into abnormal straight filaments or
paired helical filaments [37-39], aggregations of paired
helical filaments into the larger entities known as the neu-
rofibrillary tangles (NFTs) [40], hyperphosphorylated tau
[41-43], truncated tau [44], and the inability of tau to
bind microtubules due to phosphorylation of key
epitopes within the binding domain [45,46]. The human
tauP301L mutation, which is included as one of the trans-
genes harbored in 3xTg-AD mice, is commonly used in
mouse models for studying human tauopathies, such as
progressive supranuclear palsy, corticobasal degeneration,
and frontal temporal dementia (reviewed in [47]). In
these mouse models, intraneuronal inclusions of tau arise
as a result of a number of progressive phosphorylation
events on serine, threonine, and tyrosine residues [31,48],
and eventually evolve into NFTs.
Human tauP301L transgene product can be detected using
the HT7 antibody in a very limited number of 3xTg-AD
pyramidal neurons in the CA1 of the hippocampus start-
ing at 2 months of age (Figure 9A, I, Q). It was not until 6
months of age that a majority of pyramidal neurons har-
bored immunohistochemically detectable human tau. At
both the 6 and 9-month time points (Figure 9C, K, S and
9D, L, T, respectively), the staining of axonal projections
extending into the stratum radiatum began to intensify.
Qualitatively, the staining for human tauP301L transgene
product in cell bodies and processes appeared to diminish
starting at 12 months of age (Figure 9E, M, U), remaining
relatively constant at subsequent ages. Such changes in
apparent levels of human tau protein could correspond to
age-related increases in the phosphorylation state of tau,
leading to steric hindrance and/or structural alteration of
the HT7 epitope. When we examined the entorhinal cor-
tex, HT7-positive cells were not detectable until 12
months of age (Figure 10E), and no qualitative signs of
human tau transgene product accumulation, as deter-
mined by intensification of immunopositive signal, were
evident as the ages of the mice increased (Figure 10F, G,
H). As in the case for hAPPswe transgene expression, the
human tauP301L transgene product was detectable in the
amydala beginning at 6 months of age and its levels did
not appear to significantly fluctuate as the 3xTg-AD mice
aged (Figure 11A–H). Primary motor cortex appeared to
be the earliest of those examined to exhibit human
tauP301L transgene expression, where HT7-stained neurons
were consistently detectable starting at 3 months of age
(Figure 12A–H).
Oddo and colleagues recently showed evidence that
numerous phospho-tau epitopes are immunohistochem-
ically detectable in 3xTg-AD mice by 15 months of age
[49]. To assess the status of one important phospho-tau
epitope not examined in that prior report and its evolu-
tion in the 3xTg-AD mouse brain as a function of age, we
examined the phosphorylation of tau at residue Thr231
using the AT180 antibody. We could detect a limited
number of immunopositive neurons in the pyramidal
layer of the hippocampus as early as 6 months of age (Fig-
ure 13C, K), with a majority of AT180-positive cells resid-
ing in more caudal regions (Figure 13S). Robust AT180
positivity was apparent at 9 months of age in cells of the
pyramidal layer, and fibers extending into the stratum
radiatum of the hippocampus (Figure 13D, L, T). As with
the HT7 detection there appears to be a waning of AT180
staining at 12 months. However, at more advanced ages
Primary motor cortex-resident human APPswe transgene expression and Aβ peptide deposition evolve on similar timescales  as compared to the 3xTg-AD hippocampus Figure 4 (see previous page)
Primary motor cortex-resident human APPswe transgene expression and Aβ peptide deposition evolve on 
similar timescales as compared to the 3xTg-AD hippocampus. Coronal mouse brain sections (30 μm) were prepared 
from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), 
and 26 months of age (H, P, X) and were processed for immunohistochemistry to detect the human Swedish mutant amyloid 
precursor protein (hAPPswe) transgene product using the Y188 monoclonal antibody (A–H), human amyloid precursor protein 
(hAPP) and Aβ peptides using the 6E10 monoclonal antibody (I-P), and extracellular Aβ1–42 deposition using the 12F4 mono-
clonal antibody (Q-X). Primary motor cortex was examined for patterns of immunopositivity and photomicrographs were 
obtained at 10×. The insets in panels H, P, and X represent 40× digitally magnified images of designated photomicrographs for 
better visualization of immunopositive cell/pathology. Scale bar in D represents 200 μm.BMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Figure 5 (caption on next page)
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(26 months), AT180-positive signals re-intensified, sug-
gesting that these mice could exhibit a cycling phenome-
non of tau phosphorylation profiles. AT180-positive cells
were not detectable until 26 months in the entorhinal cor-
tex of 3xTg-AD mice (Figure 10P), strongly suggesting that
these mice are not experimentally suitable for studying
the effects of pathogenic tau in neuronal networks com-
prising this brain region. The amygdala stains with AT180
beginning at 6 months and this immunopositivity
remains high at later ages (Figure 11K–P), whereas the pri-
mary motor cortex less consistently stained for this phos-
pho-tau epitope (Figure 12I–P), in that immunopositive
signal could be detected only at 9, 12, and 26 months of
age.
As tau transitions to a more hyperphosphorylated state, it
undergoes a self-assembly process into intertwining 4-nm
paired helical filament (PHF) structures, further diminish-
ing the ability of tau to preserve microtubule network
integrity [50]. The monoclonal antibody PHF-1 (kindly
provided by Dr. Peter Davies) recognizes PHF structural
epitopes with robust affinity with trace reactivity towards
unmodified normal human tau [51]. We were able to
detect limited tau PHFs beginning in 15 month-old mice
within the caudal CA1 region and subiculum (Figure
14W), but it was not until mice reached 26 months of age
that we were able to consistently detect PHF-1 positive
structures throughout the hippocampus (Figure 14H, P,
X). Limited numbers of PHF-1 immunopositive cells were
detectable in the entorhinal cortex and amygdala only at
26 months of age (Figures 10X and 11X), while PHF-1
immunopositive structures were barely detectable in pri-
mary motor cortex only at 26 months of age (Figure 12X).
Amygdala-resident human APPswe transgene expression is slightly delayed, while Aβ peptide deposition evolves on a similar  timescale as compared to the 3xTg-AD hippocampus Figure 5 (see previous page)
Amygdala-resident human APPswe transgene expression is slightly delayed, while Aβ peptide deposition 
evolves on a similar timescale as compared to the 3xTg-AD hippocampus. Coronal mouse brain sections (30 μm) 
were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 
18 (G, O, W), and 26 months of age (H, P, X) and were processed for immunohistochemistry to detect the human Swedish 
mutant amyloid precursor protein (hAPPswe) transgene product using the Y188 monoclonal antibody (A–H), human amyloid 
precursor protein (hAPP) and Aβ peptides using the 6E10 monoclonal antibody (I-P), and extracellular Aβ1–42 deposition using 
the 12F4 monoclonal antibody (Q-X). Amygdala was examined for patterns of immunopositivity and photomicrographs were 
obtained at 10×. The insets in panels H, P, and X represent 40× digitally magnified images of designated photomicrographs for 
better visualization of immunopositive cell/pathology. Scale bar in D represents 200 μm.
Table 1: Antibodies Employed in Present Study
Target Epitope Antibody (Supplier) Reference
hAPP Rabbit monoclonal clone Y188 -
Amyloid precursor protein A4, corresponding to the NPXY motif 
of hAPP
(Abcam)
hAPP/Aβ Mouse monoclonal clone 6E10 Götz J, et al. [70]
Aβ amino acid residues 1–16; also cross-reacts with hAPP (Signet) Hock C, et al. [71]
Oddo S, et al. [72]
hAβ 1–42 (extracellular) C-terminus of Aβ 1–42 Mouse monoclonal clone 12F4 Parvathy, S., et al. [73]
(Covance/Signet)
hAβ 1–42 (intracellular) C-terminus of Aβ 1–42 Rabbit polyclonal anti Aβ 1–42 D'Andrea, et al [27]
(Biosource/Invitrogen)
hTau Mouse monoclonal HT7 Oddo et al [18]
Human Tau amino acid residues 159–163 (Pierce) Mercken M et al [74]
Phosphorylated Tau Mouse monoclonal AT180 Greenberg and Davies [39]
Human Tau phosphorylated residue Thr231 (Pierce) Oddo S et al. [18]
Paired Helical Filaments Monoclonal mouse anti-PHF-1 Ksiezak-Reding, et al. [37]
Human Tau phosphorylated on amino acid residues Ser396 and 
Ser404 associated with paired helical filaments
(Dr. Peter Davies, Albert Einstein School of Medicine) Clinton, et al. [68]
F4/80 Rat anti mouse F4/80 Janelsins et al. [52]
(AbD Serotec)
Cell surface glycoprotein on mature macrophages that is a 
member of the EGF-TM7 family
GFAP Rabbit polyclonal anti-GFAP Shaftel S, et al. [75]
Cell surface marker (glial fibrillary acidic protein) for mature 
astrocytes
(Dako Cytomation)BMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Figure 6 (caption on next page)
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Age-related Patterns of Microglia and Astrocyte Staining
Inflammatory processes have long been posited as serving
integral roles in initiating and/or propagating AD-associ-
ated pathology within the human brain, as the elabora-
tion of inflammatory cytokine expression and other
markers of inflammation is more pronounced in individ-
uals with known AD pathology. We previously reported
significant enhancement of pro-inflammatory cytokine
and chemokine expression and concomitant increases in
region-specific microglial cell numbers, prior to the onset
of overt amyloid pathology in young 3xTg-AD mice [52].
Herein, we assessed the status of two abundant non-neu-
ronal cells traditionally activated in the setting of AD:
microglia and astrocytes. The role of microglia and their
accumulation at the sites of dense neuritic plaques has
been described [53-55]. Immunohistochemical analysis
of 3xTg-AD hippocampal brain tissue using an antibody
specific for the microglia/macrophage surface marker, F4/
80, revealed a qualitative enhancement of microglia stain-
ing from 2 (Figure 15A, I, Q) to 3 months of age (Figure
15B, J, R). The pattern of microglial distribution appeared
rather uniform throughout the hippocampus from 3 to 15
months of age (Figure 15). Beginning at 18 months in the
most caudal sections of hippocampus (Figure 15W) and
continuing at 26 months (Figure 15X), there was a
marked change in the distribution of microglia, with these
cells appearing to assemble into dense aggregates, remi-
niscent of amyloid plaque-like structures. Microglial
staining patterns in the entorhinal cortex were similar to
those in hippocampus, except that aggregation of F4/80-
positive cells was not overtly evident in 18 and 26 month-
old 3xTg-AD mice (Figure 16A–H). F4/80-positive micro-
glia in both the amygdala and primary motor cortex
exhibited age-related distributions similar to those of the
hippocampal formation (Figures 17A–H and 18A–H,
respectively).
Astrocytes are involved in many different functions in the
brain, including structural integrity of the blood brain
barrier, support of neuronal synapses by ion regulation
and removal of glutamate [56]. Although it is believed
that they are not directly responsive to primary insults,
astrocytes react to inflammatory events in the brain, rely-
ing upon pro-inflammatory molecules elaborated from
activated microglia [55]. Once signaled to do so, astro-
cytes can perpetuate inflammatory events in the brain via
expression of iNOS and the enzyme argininosuccinate
synthetase [57,58]. Glial fibrillary acidic protein (GFAP) is
often employed as a marker of astrocytic activation.
GFAP-expressing astrocytes were readily visible in 3xTg-
AD mice at 2 months of age throughout the hippocampus
(Figure 19A, I, Q), with limited signs of activation in the
entorhinal cortex, amygdala, and primary motor cortex at
this age (Figures 16I, 17I, and 18I). There appeared to be
a qualitative decline in staining intensity in rostral hip-
pocampal regions beginning at 15 months of age (Figure
19F) and continuing through 26 months of age (Figure
19H). However, the overall pattern of activated astrocyte
staining within the hippocampus remained relatively con-
stant as a function of age. More robust GFAP-positive
astrocyte staining in the entorhinal cortex was more
apparent at the 18- and 26-month time points (Figure
16O, P), while GFAP staining was less detectable, but con-
stant at ages greater than 18 months in amygdala and pri-
mary motor cortex (Figures 17O, P and 18O, P,
respectively).
Discussion and conclusion
The 3xTg-AD mouse serves as an informative preclinical
model employed ever increasingly in the examination of
mechanisms underlying AD, as well as for the vetting of
experimental AD-modifying therapeutics. The present
study was designed to immunohistochemically document
the evolution of transgene expression, amyloid deposi-
tion, pathogenic tau phosphorylation, astrogliosis, and
microglial activation throughout the hippocampus and
entorhinal cortex over a 26-month period in 3xTg-AD
mice. A summary of pathological progression and qualita-
tive severity scoring in these mice is illustrated in Table 2.
Previously published reports employing the 3xTg-AD
model have primarily focused upon mechanisms/pathol-
ogies pertaining to either early or late-stage disease, and
have provided limited insight into the overall progression
of evolving AD-related pathologies using a systematic
immunohistochemical approach. Gaining a detailed
understanding as to how hAPPswe and tauP301L transgene
6E10 immunohistochemistry reveals differential cell-associated hAPP/Aβ accumulation patterns and markedly late-stage extra- cellular plaque deposition in 3xTg-AD mouse hippocampus Figure 6 (see previous page)
6E10 immunohistochemistry reveals differential cell-associated hAPP/Aβ accumulation patterns and markedly 
late-stage extracellular plaque deposition in 3xTg-AD mouse hippocampus. Coronal mouse brain sections (30 μm) 
were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 
18 (G, O, W), and 26 months of age (H, P, X) and were processed for immunohistochemistry using the 6E10 monoclonal 
antibody to detect both human amyloid precursor protein (hAPP) and Aβ peptides. CA1 hippocampal sections at Bregma -1.8 
mm (A–H), at Bregma -2.5 mm (I–P), and at Bregma -2.8 mm (Q-X), were examined for regional and temporal patterns of 
hAPPswe transgene/Aβ peptide expression and photomicrographs were obtained at 10×. The inset in panel X represents a 40× 
digitally magnified image of the photomicrograph for better visualization of stained cell morphology. Scale bar in D represents 
200 μm.BMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Figure 7 (caption on next page)
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expression relates temporally and spatially to the appear-
ance of pathogenic Aβ peptide- and hyperphosphorylated
tau-related pathologies enables the informed design and
implementation of future studies. Moreover, given that
these AD-related pathologies exhibit subtle regional dif-
ferences within the 3xTg-AD mouse brain, the informa-
tion gleaned from systematic immunohistochemical
assessment hones the focus of endpoint analyses on brain
regions more or less severely impacted depending upon
the hypotheses being tested.
We found that patterns of intracellular Aβ peptide immu-
noreactivity do not correlate with the patterns of human
APPswe transgene expression in 3xTg-AD mice. Both Aβ1–
42-specific antibodies that were employed, which have
been pre-absorbed to eliminate binding to non-Aβ1–42
species, exhibit distinct patterns of staining that lie out-
side of the pyramidal cell layer of the hippocampus and
layer II/III of the entorhinal cortex. These cell layers, how-
ever, show heavy immunoreactivity for human APPswe
transgene product. A number of groups have demon-
strated that APP is synthesized at the cell body and under-
goes anterograde axonal transport to distal compartments
where it is ultimately proteolytically processed (reviewed
in [59]). Neurons emanating from layer III of the entorhi-
nal cortex extend bilaterally into the CA1 and CA3 of the
hippocampus and subiculum [60], whereas pyramidal
neurons from the CA1 of the hippocampus project into
layer V of the entorhinal cortex and to areas of the subic-
ulum [61]. This evidence taken together with the observed
patterns of hAPPswe transgene expression within cells that
comprise the perforant pathway in 3xTg-AD mice, it is rea-
sonable to propose that the Aβ1–42 cleavage product is
generated and accumulates at termini.
We should note that the cells harboring intracellular Aβ
are purported to be neurons, but whether they represent
the sole cell type physiologically influenced by intracellu-
lar Aβ peptide accumulation is unlikely. It is known that
other cell types [62], including microglia [53] and astro-
cytes [63], are able to pinocytize and phagocytize extracel-
lular Aβ1–42. These cells may represent viable targets for
the deleterious effects attributed to intracellular Aβ pep-
tides. Cummings and colleagues demonstrated previously
that Aβ peptides, produced initially by neurons and
deposited at neuronal terminals, are readily able to form
higher order aggregates [64]. This may also explain the
spatial alterations found with in the hippocampus where
plaque burden is observed at earlier ages in the more cau-
dal regions of the 3xTg-AD brain. Hence, the anatomical
interconnectivity of these projections and biogenesis and
subsequent proteolytic processing of hAPPswe  likely
underlie the dissonant patterns of Aβ and hAPPswe immu-
noreactivity observed in the CA1, subiculum, and the
entorhinal cortex of 3xTg-AD mice.
It was somewhat surprising that extracellular Aβ1–42
plaques were not readily detectable in male 3xTg-AD mice
in our study until 15 months in the caudal hippocampus
and 18 months in cortical structures, findings that are in
conflict with Oddo and colleagues that stated in their orig-
inal 2003 report that 3xTg-AD mice exhibit amyloid
plaques beginning at 6 months of age in the frontal cortex
[17]. These disparate results may be the result of the anti-
bodies employed or the genders of mice studied in each
study, but such details are absent from the original report
making it difficult to resolve this issue. Other explana-
tions may exist, including loss of phenotype due to a pro-
gressive loss of transgene copies with successive breeding,
different founder/line of mice provided to outside investi-
gators compared to the mice described in the original
report, as well as differences in housing conditions. The
mice used in the present study were pathogen-free and
were maintained in a pathogen-free facility throughout
the duration of the experiments. Moreover, we have not
observed any overt reduction in transgene copy numbers
over the 12+ generations we have housed 3xTg-AD mice
within our animal colony. However, determining the dif-
ferences in pathological progression and elucidating the
underlying cause(s) is important for generation of consist-
ent data sets across different laboratories that are mean-
ingful and provide generally applicable mechanistic
insight into AD-related processes.
Extracellular Aβ 1–42 deposition is not immunohistochemically detectable in male 3xTg-AD mouse hippocampus until 15  months of age Figure 7 (see previous page)
Extracellular Aβ 1–42 deposition is not immunohistochemically detectable in male 3xTg-AD mouse hippocam-
pus until 15 months of age. A monoclonal antibody specific for human Aβ1–42 (12F4; Signet) was incubated with 20 month-
old 3xTg-AD mouse brain sections alone (A), or with a 200-fold molar excess of the cognate reverse peptide (B), forward 
peptide (C), or no-primary control (D) according to a protocol designed to detect extracellular Aβ1–42. Coronal mouse brain 
sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (E, M, U), 3 (F, N, V), 6 (G, O, W), 9 (H, P, X), 12 (I, 
Q, Y), 15 (J, R, Z), 18 (K, S, AA), and 26 months of age (L, T, AB) and were processed for immunohistochemistry using the 
12F4 antibody to detect extracellular Aβ1–42 peptide accumulation. CA1 hippocampal sections at Bregma -1.8 mm (E-L), at 
Bregma -2.5 mm (M-T), and at Bregma -2.8 mm (U-AB), were examined for regional and temporal patterns of extracellular 
Aβ1–42 deposition and photomicrographs were obtained at 10×. The inset in panel AB represents a 40× digitally magnified 
image of the photomicrograph for better visualization of stained cell morphology. Scale bar in D represents 200 μm.BMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Figure 8 (caption on next page)
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Similar to the hAPPswe transgene product, human tauP301L,
as detected with the HT7 antibody, appears immunohis-
tochemically at 2–3 months of age in 3xTg-AD mice. This
is not surprising given that both hAPPswe and tauP301L
transgenes are transcriptionally controlled by the Thy 1.2
promoter, and that the transgenes are genetically linked
due to the method by which the 3xTg-AD mice were
derived [17]. Using phospho-epitope specific antibodies,
Sahara and colleagues showed that tau proceeds through
a series of post-translational phosphorylation events that
progressively lead to increased insolubility and decreased
functionality [31]. We were able to detect phosphoryla-
tion at the Thr231 amino acid residue of tau, an indica-
tion of pathogenic progression, as early as 6 months of age
in cells residing within the pyramidal layer of the hippoc-
ampus. This evidence suggests that tau dysfunction con-
tributes to AD-related pathophysiology in 3xTg-AD mice
at ages earlier than purported in previously published
studies [18]. Oddo and colleagues reported that the
Thr231 phospho-epitope of tau is not detectable until 12
months of age. Given our findings, designs of future stud-
ies seeking to dissect the differential influences of APPswe
and tauP301L  on brain physiology need to take into
account the overlapping temporal expression patterns of
the 3xTg-AD transgenes.
We have previously demonstrated that various inflamma-
tory events correspond to the presentation of early (< 6
months of age) intracellular Aβ pathology in 3xTgAD
mice [52]. Specifically, the pro-inflammatory cytokine
tumor necrosis factor-alpha (TNF-α) and chemokine
monocyte chemoattractant protein-1 (MCP-1) are
expressed at heightened levels in a region-specific pattern,
and these enhanced molecule expression profiles correlate
with increased numbers of microglia specifically within
3xTg-AD mice as compared to age-matched, non-trans-
genic control mice. As such, it was imperative in the
present study to continue to monitor alterations in glial
marker expression as these mice age as staining intensity
and/or pattern changes could provide insight into patho-
physiology. We observed a clustering of F4/80-positive
microglia/monocyte cells within areas exhibiting heavy
amyloid burden in 3xTg-AD mice at 15 to 26 months of
age. It is likely that this pattern of microglial accumulation
is indicative of association with Aβ-containing plaques
similar to that observed in human AD brain. Interestingly,
3xTg-AD mice do not show noticeable age-related
enhancement GFAP-positive astrocyte staining intensities,
which markedly differentiates this model from what has
been documented in other AD mouse models, including
the PDAPP mouse [65]. These differences in activation of
astrocytes may inherently relate to the relative strength
and/or cell type expression specificities of the promoters
employed to drive each of the respective AD-related trans-
genes (reviewed by [66]).
Other investigators have shown that amyloidogenic
mouse models of AD exhibit gender-related differences in
severity of pathology [67]. In this study we present a time
course of AD-related pathological progression solely for
male 3xTg-AD mice in order to more finely assess interme-
diate ages for subtle region-specific differences. While
Clinton et al. have shown that sexual dimorphisms in cog-
nition and stress responses are apparent between male
and female 3xTgAD mice [68], that study did not include
an extensive histological comparison of brains from the
two genders. Carroll and colleagues more recently
reported that female 3xTg-AD mice exhibit an earlier
onset of AD pathology and this may be a consequence of
progesterone and estrogen-mediated signaling mecha-
nisms [69]. Given these gender-specific differences in time
of onset and severity of behavioral phenotype it is imper-
ative that future experimental therapeutics be vetted in
both male and female 3xTg-AD mice. Moreover, the
underlying neuroinflammatory state of each gender is
likely disparate and may markedly impact the efficacy
and/or safety profile of a particular therapeutic, especially
if that modality is immune-based in nature. The 3xTg-AD
model provides an informative platform on which to test
new therapeutic modalities, but the regional, temporal,
and gender-specific subtleties and limitations of this
model must be fully appreciated before this model is ele-
Intracellular Aβ 1–42 accumulation is immunohistochemically detectable by 3 months of age in 3xTg-AD mouse hippocampus Figure 8 (see previous page)
Intracellular Aβ 1–42 accumulation is immunohistochemically detectable by 3 months of age in 3xTg-AD mouse 
hippocampus. A polyclonal antibody specific for human Aβ1–42 (Biosource/Invitrogen) was incubated with 20 month-old 
3xTg-AD mouse brain sections alone (A), or with a 200-fold molar excess of the cognate reverse peptide (B), forward peptide 
(C), or no-primary control (D) according to a protocol designed to detect intracellular Aβ1–42 [27]. Arrows indicate immuno-
positive cells, while "*" depicts non-specific signal due to precipitant. Coronal mouse brain sections (30 μm) were prepared 
from 3xTg-AD mice sacrificed at 2 (E, M, U), 3 (F, N, V), 6 (G, O, W), 9 (H, P, X), 12 (I, Q, Y), 15 (J, R, Z), 18 (K, S, AA), 
and 26 months of age (L, T, AB) and were processed for immunohistochemistry to detect intracellular Aβ1–42 peptide accu-
mulation using the Biosource/Invitrogen anti-Aβ1–42 polyclonal antibody. CA1 hippocampal sections at Bregma -1.8 mm (E-L), 
at Bregma -2.5 mm (M-T), and at Bregma -2.8 mm (U-AB), were examined for regional and temporal patterns of intracellular 
Aβ1–42 and photomicrographs were obtained. The insets in panels U-AB represent digitally magnified images of designated 
photomicrographs for more optimal visualization of stained cell morphology. Scale bar in D represents 50 μm.BMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Human tauP301L transgene expression exhibits regionally and temporally disparate staining patterns in the 3xTg-AD mouse hip- pocampus Figure 9
Human tauP301L transgene expression exhibits regionally and temporally disparate staining patterns in the 
3xTg-AD mouse hippocampus. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 
(A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), and 26 months of age (H, P, X) and 
were processed for immunohistochemistry using the HT7 monoclonal antibody to detect human tauP301L transgene expression. 
CA1 hippocampal sections at Bregma -1.8 mm (A–H), at Bregma -2.5 mm (I–P), and at Bregma -2.8 mm (Q–X), were exam-
ined for regional and temporal patterns of human tauP301L and photomicrographs were obtained at 10×. The inset in panel X 
represents a 40× digitally magnified image of the photomicrograph for better visualization of stained cell morphology. Scale bar 
in D represents 200 μm.
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Tau pathological hallmarks do not arise in the entorhinal cortex until 26 months of age Figure 10
Tau pathological hallmarks do not arise in the entorhinal cortex until 26 months of age. Coronal mouse brain sec-
tions (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 
15 (F, N, V), 18 (G, O, W), and 26 months of age (H, P, X) and were processed for immunohistochemistry to detect the 
human tau P301L mutant transgene product using the HT7 monoclonal antibody (A–H), human phospho-tau (Thr231) using 
the AT180 monoclonal antibody (I–P), and paired helical filament pathology using the PHF-1 monoclonal antibody (Q–X). 
Entorhinal cortex was examined for patterns of immunopositivity and photomicrographs were obtained at 10×. The insets in 
panels H, P, and X represent a 40× digitally magnified images of designated photomicrographs for better visualization of immu-
nopositive cell/pathology. Scale bar in D represents 200 μm.
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The phospho-tau (Thr231) epitope is readily detectable, but paired helical filament pathology is virtually absent in the amygdala  of 3xTg-AD mice Figure 11
The phospho-tau (Thr231) epitope is readily detectable, but paired helical filament pathology is virtually 
absent in the amygdala of 3xTg-AD mice. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice 
sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), and 26 months of age 
(H, P, X) and were processed for immunohistochemistry to detect the human tau P301L mutant transgene product using the 
HT7 monoclonal antibody (A–H), human phospho-tau (Thr231) using the AT180 monoclonal antibody (I–P), and paired heli-
cal filament pathology using the PHF-1 monoclonal antibody (Q–X). Amygdala was examined for patterns of immunopositivity 
and photomicrographs were obtained at 10×. The insets in panels H, P, and X represent a 40× digitally magnified images of 
designated photomicrographs for better visualization of immunopositive cell/pathology. Scale bar in D represents 200 μm.
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Tau pathological hallmarks exhibit disparate staining patterns in the primary motor cortex of 2–26 month-old 3xTg-AD mice Figure 12
Tau pathological hallmarks exhibit disparate staining patterns in the primary motor cortex of 2–26 month-old 
3xTg-AD mice. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, 
R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), and 26 months of age (H, P, X) and were processed 
for immunohistochemistry to detect the human tau P301L mutant transgene product using the HT7 monoclonal antibody (A–
H), human phospho-tau (Thr231) using the AT180 monoclonal antibody (I–P), and paired helical filament pathology using the 
PHF-1 monoclonal antibody (Q–X). Primary motor cortex was examined for patterns of immunopositivity and photomicro-
graphs were obtained at 10×. The insets in panels H, P, and X represent 40× digitally magnified images of designated photom-
icrographs for better visualization of immunopositive cell/pathology. Scale bar in D represents 200 μm.
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The phospho-tau epitope Thr231 is immunohistochemically detectable in 3xTg-AD mouse hippocampus by 6 months of age Figure 13
The phospho-tau epitope Thr231 is immunohistochemically detectable in 3xTg-AD mouse hippocampus by 6 
months of age. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, 
R), 6 (C, K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), and 26 months of age (H, P, X) and were processed 
for immunohistochemistry using the AT180 monoclonal antibody to detect phospho-tau (Thr231) expression. CA1 hippocam-
pal sections at Bregma -1.8 mm (A–H), at Bregma -2.5 mm (I–P), and at Bregma -2.8 mm (Q–X), were examined for regional 
and temporal patterns of human phospho-tau and photomicrographs were obtained at 10×. The inset in panel X represents a 
40× digitally magnified image of the photomicrograph for better visualization of stained cell morphology. Scale bar in D repre-
sents 200 μm.
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Paired helical filament pathology does not arise until 18–26 months of age in 3xTg-AD mouse hippocampus Figure 14
Paired helical filament pathology does not arise until 18–26 months of age in 3xTg-AD mouse hippocampus. 
Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 
(D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), and 26 months of age (H, P, X) and were processed for immunohisto-
chemistry using the PHF-1 monoclonal antibody to detect phospho-tau (Ser396 and Ser404) associated with paired helical fila-
ment pathology. CA1 hippocampal sections at Bregma -1.8 mm (A–H), at Bregma -2.5 mm (I–P), and at Bregma -2.8 mm (Q–
X), were examined for regional and temporal patterns of PHF-1 immunopositivity and photomicrographs were obtained at 
10×. The inset in panel X represents a 40× digitally magnified image of the photomicrograph for better visualization of stained 
cell morphology. Scale bar in D represents 200 μm.
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Microglial staining patterns modulate as a function of age in the 3xTg-AD mouse hippocampus Figure 15
Microglial staining patterns modulate as a function of age in the 3xTg-AD mouse hippocampus. Coronal mouse 
brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, K, S), 9 (D, L, T), 12 (E, 
M, U), 15 (F, N, V), 18 (G, O, W), and 26 months of age (H, P, X) and were processed for immunohistochemistry using the 
F4/80 monoclonal antibody to detect brain-resident microglia/macrophages. CA1 hippocampal sections at Bregma -1.8 mm 
(A–H), at Bregma -2.5 mm (I–P), and at Bregma -2.8 mm (Q–X), were examined for regional and temporal patterns of F4/80 
immunopositivity and photomicrographs were obtained at 10×. The inset in panel X represents a 40× digitally magnified image 
of the photomicrograph for better visualization of stained cell morphology. Scale bar in D represents 200 μm.
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vated to "golden standard" status in the field of AD
research.
Methods
Transgenic Mice
The 3xTg-AD mice (B1 line) were kindly provided by
Frank LaFerla (University of California, Irvine; [17]). All
mice were housed and bred in accordance with University
of Rochester requirements for animal welfare and care.
Homozygous 3xTg-AD mice were monogamously mated
to produce offspring, which were housed until sacrificed
at the designated age. Mice were sacrificed via pentabarbi-
tol overdose and subsequently transcardiac perfused with
heperanized saline, followed by 4% paraformaldehyde in
0.1 M phosphate buffer (PB). Brains were removed and
post-fixed overnight in 4% paraformaldehyde in 0.1 M
PB, followed by equilibration in 20% sucrose in 0.1 M
phosphate-buffered saline (PBS) and then 30% sucrose in
0.1 M PBS. Brains were coronally sectioned on a freezing
stage sliding microtome (Microm, Walldorf, Germany) at
30 μm and stored in cryoprotectant at -20°C until immu-
nohistochemical processing.
Nissl Staining
Brain sections were washed with 0.15 M PB for 2 h to
remove the cryoprotectant, and mounted on Superfrost®
Entorhinal cortex microglial and astrocytic staining patterns evolve on a similar timescale as observed in the 3xTg-AD hippoc- ampus Figure 16
Entorhinal cortex microglial and astrocytic staining patterns evolve on a similar timescale as observed in the 
3xTg-AD hippocampus. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I), 3 
(B, J), 6 (C, K), 9 (D, L), 12 (E, M), 15 (F, N), 18 (G, O), and 26 months of age (H, P) and were processed for immunohisto-
chemistry to detect activated microglia using an anti-F4/80 specific monoclonal antibody (A–H) and astrocytes using an anti-
GFAP specific monoclonal antibody (I–P). Entorhinal cortex was examined for patterns of immunopositivity and photomicro-
graphs were obtained at 10×. The insets in panels H and P represent 40× digitally magnified images of designated photomicro-
graphs for better visualization of immunopositive cells. Scale bar in D represents 200 μm.
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Plus slides (VWR International, West Chester, PA) and
allowed to dry completely. The slides were subsequently
hydrated in dH20 for 5 min. before being stained with
0.02% Cresyl violet Acetate in 0.25% Acetic acid for 30
min. Sections were rinsed in 3 changes of dH20, and
placed in 50% ethanol for 1 min. followed by 70% for 1
min. to destain. Sections were allowed to dry and then
cleared by dipping in xylene before being coverslipped.
Antibodies
The following antibodies were used at the designated
working dilutions: anti-amyloid precursor protein A4,
corresponding to the NPXY motif of hAPP, (Clone Y188;
AbCam, Cambridge, MA, 1:750); anti-hAPP/amyloid-
beta reactive to amino acid residue 1–16 of beta-amyloid
(6E10; Covance, Berkeley, CA; 1:1000); anti-amyloid beta
1–42 clone 12F4 reactive to the C-terminus of beta-amy-
loid and specific for the isoform ending at amino acid 42
(Covance/Signet, Berkeley, CA, 1:1000); anti-amyloid
beta 1–42 polyclonal antibody for intracellular amyloid-
beta staining (Invitrogen, Carlsbad, CA, formerly Bio-
source, Hopkinton, MA 1:1000); anti-human tau HT7,
reactive to residues 159 to 163 (Pierce, Rockford, IL;
1:200); anti-human phosphorylated tau AT180, specific
Amygdala-resident microglial and astrocytic staining patterns evolve on a similar timescale as observed in the 3xTg-AD hippoc- ampus Figure 17
Amygdala-resident microglial and astrocytic staining patterns evolve on a similar timescale as observed in the 
3xTg-AD hippocampus. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I), 3 
(B, J), 6 (C, K), 9 (D, L), 12 (E, M), 15 (F, N), 18 (G, O), and 26 months of age (H, P) and were processed for immunohisto-
chemistry to detect activated microglia using an anti-F4/80 specific monoclonal antibody (A–H) and astrocytes using an anti-
GFAP specific monoclonal antibody (I–P). Amygdala was examined for patterns of immunopositivity and photomicrographs 
were obtained at 10×. The insets in panels H and P represent 40× digitally magnified images of designated photomicrographs 
for better visualization of immunopositive cells. Scale bar in D represents 200 μm.
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for htau phosphorylated at the Thr231 residue (Pierce,
Rockford, IL; 1:200); anti-human phosphorylated tau
PHF-1 (gift from Dr. Peter Davies, Albert Einstein College
of Medicine; 1:30); anti-glial fibrillary acidic protein
GFAP (Dako Cytomation, Glostrup, Denmark; 1:1000);
and an antibody specific for the microglial/monocytic cell
surface marker F4/80 (AbD Serotec, Raleigh, NC; 1:500).
Specificity of the anti-Aβ1–42 antibodies (12F4 from Cov-
ance/Signet for extracellular Aβ staining and anti-Aβ1–42
polyclonal from Biosource/Invitrogen for intracellular Aβ
staining) was confirmed using peptide competition exper-
iments. The results of these assessments are illustrated in
Figures 7 and 8, respectively.
Immunohistochemistry
Brain sections were washed with 0.15 M PB for 2 h to
remove the cryoprotectant, then incubated with 3% H2O2
in 0.15 M PB for 20 min. to quench endogenous peroxi-
dase activity. For Aβ peptide-specific stains, the sections
were treated with 70% formic acid for 15 min. for epitope
retrieval. For the intracellular Aβ1–42stain, we employed a
microwave/Target buffer (Dako Cytomation, Glostrup,
Primary motor cortex microglial and astrocytic staining patterns evolve on a similar timescale as observed in the 3xTg-AD hip- pocampus Figure 18
Primary motor cortex microglial and astrocytic staining patterns evolve on a similar timescale as observed in 
the 3xTg-AD hippocampus. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, 
I), 3 (B, J), 6 (C, K), 9 (D, L), 12 (E, M), 15 (F, N), 18 (G, O), and 26 months of age (H, P) and were processed for immuno-
histochemistry to detect activated microglia using an anti-F4/80 specific monoclonal antibody (A–H) and astrocytes using an 
anti-GFAP specific monoclonal antibody (I–P). Primary motor cortex was examined for patterns of immunopositivity and pho-
tomicrographs were obtained at 10×. The insets in panels H and P represent 40× digitally magnified images of designated pho-
tomicrographs for better visualization of immunopositive cells. Scale bar in D represents 200 μm.
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GFAP-positive astrocyte staining remains relatively constant as a function of age in 3xTg-AD mouse hippocampus Figure 19
GFAP-positive astrocyte staining remains relatively constant as a function of age in 3xTg-AD mouse hippoc-
ampus. Coronal mouse brain sections (30 μm) were prepared from 3xTg-AD mice sacrificed at 2 (A, I, Q), 3 (B, J, R), 6 (C, 
K, S), 9 (D, L, T), 12 (E, M, U), 15 (F, N, V), 18 (G, O, W), and 26 months of age (H, P, X) and were processed for immu-
nohistochemistry using a GFAP-specific monoclonal antibody to detect brain-resident astrocytes. CA1 hippocampal sections at 
Bregma -1.8 mm (A–H), at Bregma -2.5 mm (I–P), and at Bregma -2.8 mm (Q–X), were examined for regional and temporal 
patterns of GFAP immunopositivity and photomicrographs were obtained at 10×. The inset in panel X represents a 40× digit-
ally magnified image of the photomicrograph for better visualization of stained cell morphology. Scale bar in D represents 200 
μm.
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Table 2: Qualitative assessment of pathological progression by region in male 2–26 month-old 3xTg-AD mice.
Antigen Age (months)
h A P P 2369 1 21 5 1 8 2 6
P r i m a r y  m o t o r  c o r t e x +++++ + + +
Amygdala - - + + ++ ++ ++ ++
R o s t r a l  H i p p o c a m p u s  C A 1 ++++ + ++ + + + + +
M e d i a l  H i p p o c a m p u s  C A 1 ++++ + ++ + + + + +
C a u d a l  H i p p o c a m p u s  C A 1 / S u b i c u l u m ++++ + ++ + + + + +
E n t o r h i n a l  C o r t e x ++++ + ++ + + + + +
hAPP/Aβ
Primary motor cortex + + ++ ++ ++ ++ +++ +++
Amygdala + + ++ ++ ++ ++ +++ +++
Rostral Hippocampus CA1 - - + + ++ ++ +++ +++
Medial Hippocampus CA1 - - + + ++ ++ +++ +++
Caudal Hippocampus CA1/Subiculum - + + + ++ +++ +++ +++
Entorhinal Cortex - - + + + + +++ +++
hAβ 1–42 (Extracellular)
P r i m a r y  m o t o r  c o r t e x ----- - + + +
A m y g d a l a ----- - + ++ + +
R o s t r a l  H i p p o c a m p u s  C A 1 ----- - + + +
M e d i a l  H i p p o c a m p u s  C A 1 ----- - + + +
C a u d a l  H i p p o c a m p u s  C A 1 / S u b i c u l u m ----- + + ++ + +
E n t o r h i n a l  C o r t e x ----- - ++ + +
hAβ 1–42 (Intracellular)
Primary motor cortex +/- +/- + + ++ ++ ++ ++
Amygdala +/- +/- + + ++ ++ ++ ++
Rostral Hippocampus CA1 +/- + ++ ++ ++ ++ ++ ++
Medial Hippocampus CA1 + ++ ++ ++ ++ ++ ++ ++
Caudal Hippocampus CA1/Subiculum + ++ ++ ++ ++ ++ ++ ++
E n t o r h i n a l  C o r t e x + / - ++++ + + +
Human Tau
P r i m a r y  m o t o r  c o r t e x + / - ++++ + + +
Amygdala - - + + + + + +
Rostral Hippocampus CA1 +/- +/- + + + + + +
Medial Hippocampus CA1 +/- +/- + + + + ++ ++
Caudal Hippocampus CA1/S u b i c u l u m + / - + / - +++ + + + + +
E n t o r h i n a l  C o r t e x -----+ / -+ / -+ / -
Phospho-hTau (Thr231)
Primary motor cortex - - - + + +/- +/- +
Amygdala - - + ++ ++ + + ++
Rostral Hippocampus CA1 - - +/- + + +/- +/- +
Medial Hippocampus CA1 - - +/- + + + +/- ++
Caudal Hippocampus CA1 / S u b i c u l u m - -+++ + + +
E n t o r h i n a l  C o r t e x ----- - - + / -
Paired Helical Filaments
P r i m a r y  m o t o r  c o r t e x ----- - - -
A m y g d a l a ----- - - -
R o s t r a l  H i p p o c a m p u s  C A 1 ----- - + / - +
M e d i a l  H i p p o c a m p u s  C A 1 ----- - + / - +
C a u d a l  H i p p o c a m p u s  C A 1 / S u b i c u l u m ----- - + +
E n t o r h i n a l  C o r t e x ----- - - + / -
Microglia
P r i m a r y  m o t o r  c o r t e x +++++ + + + + +BMC Neuroscience 2008, 9:81 http://www.biomedcentral.com/1471-2202/9/81
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Denmark) epitope retrieval method as described previ-
ously [27]. Briefly, the brain sections were washed and
peroxidase activity quenched. The sections were mounted
on to slides and allowed to dry. The Target buffer was
heated to 98°C in a microwave (GE, Louisville, KY), the
slides submerged into the buffer and placed in the micro-
wave, twice for 3 min. at 450 W, and allowed to rest for 5
min. between microwave steps. Brain sections were simi-
larly processed for immunohistochemistry as detailed
below. The sections were washed and permeabilized in
0.15 M PB and 0.4% Triton X-100, followed by blocking
in 0.15 M PB with 10% normal goat serum, and 0.4% Tri-
ton X-100. After blocking, the sections were incubated in
0.15 M PB with 1% normal goat serum, and 0.4% Triton
X-100, with the designated primary antibody. The sec-
tions were washed with 0.15 M PB, followed by an incu-
bation with the appropriate secondary biotin-conjugated
secondary antibodies (Vector Labs, Burlingame, CA;
1:1000) in 0.15 M PB with 1% normal goat serum, and
0.4% Triton X-100. The sections were washed with 0.15 M
PB with 1% normal goat serum and 0.4%Triton X-100,
and incubated in the avidin-biotin complex (Vector Labs
Vectastain ABC System as per manufacturer's protocol,
Vector Labs, Burlingame, CA). Sections were washed in
0.15 M PB followed by rinses in dH2O. The sections were
developed with nickel-enhanced DAB (Vector Labs, Burl-
ingame, CA). Sections were mounted on Superfrost®Plus
slides (VWR International, West Chester, PA) cover-
slipped and viewed using an Olympus AX-70 microscope
and motorized stage (Olympus, Center Valley, PA) and
the MCID 6.0 Imaging software (Interfocus Imaging sub-
sidiary of GE Healthcare, Cambridge, England).
Qualitative scoring of immunohistochemical staining 
intensities
Time points were compared to one another within a par-
ticular antibody staining group. Images were analyzed
using the relative optical density (ROD) score in the
MCID 6.0 Imaging software (Interfocus Imaging subsidi-
ary of GE Healthcare, Cambridge, England). Sections of
all the mice, corresponding to the areas of study, were
scored according to the following schema: (-) indicates no
staining present, (+/-) indicates limited number of cells/
structures showing evidence of staining, (+) denotes con-
sistent expression of the marker, (++) represents an ele-
vated expression measured in ROD of Δ 0.075 to 0.250,
and (+++) represents a further increase in staining as indi-
cated by a change in ROD of Δ 0.251 greater than (+)
staining intensities.
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